Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial
Stopped: The exclusion criteria were stringent and enrollment was slow.
United States17 participantsStarted 2004-09
Plain-language summary
Full Title: A Randomized Controlled Trial of Procrit for the Prevention of Acute Renal Failure in Patients Receiving Intravenous Contrast
Primary Objective: To evaluate the efficacy of a one-time dose of intravenous erythropoietin administration in the prevention or attenuation of contrast-induced acute renal failure.
Secondary Objectives: To evaluate serum and urinary markers of renal injury, including KIM-1, BMP-7, and TGF-b, along with other biomarkers, in subjects receiving intravenous contrast and correlate their expression with clinical outcomes
Study Design: Prospective, multi-centered, randomized, double blind, placebo controlled trial of a one-time dose of EPO. Subjects will be followed for seven days or until hospital discharge, whichever is longer. Total estimated study duration 3 years.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subjects age 18 and over and of either gender.
✓. Scheduled to receive CT scan with intravenous contrast dye.
✓. Non diabetics or subjects with type 1 or 2 diabetes mellitus
✓. Written informed consent.
✓. Subjects who are on diuretics and non-steroidal inflammatory agents will not be excluded.
✓. Subjects who have received n-acetylcysteine or sodium bicarbonate pre CT scan will not be excluded
Exclusion criteria
✕. Pregnant or lactating women.
✕. End-stage renal disease (on hemodialysis or peritoneal dialysis)
✕. A known history of acute renal failure
✕. Subjects receiving glucophage/metformin or glucovance
✕
What they're measuring
1
Comparison of incidence of rise in serum creatinine of 25% or more in the study group vs. placebo